Search for content, post, videos

First healthy volunteer dosed in the Herantis’ Phase 1a trial

Herantis Pharma has announced the dosing of the first healthy volunteer in the Phase 1a clinical study for HER-096. The Phase 1a clinical study will assess safety, tolerability, and blood-brain barrier penetration of subcutaneously administered HER-096. “We are excited to start the Phase 1a
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.